Cargando…

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma

BACKGROUND: The study objective was to evaluate the effect of everolimus (EVR) in combination with reduced tacrolimus (rTAC) compared with a standard TAC (sTAC) regimen on hepatocellular carcinoma (HCC) recurrence in de novo living-donor liver transplantation recipients (LDLTRs) with primary HCC at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sapisochin, Gonzalo, Lee, Wei Chen, Joo, Dong Jin, Joh, Jae-Won, Hata, Koichiro, Soin, Arvinder Singh, Veldandi, Uday Kiran, Kaneko, Shuhei, Meier, Matthias, Leclair, Denise, Sunkara, Gangadhar, Jeng, Long Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700399/ https://www.ncbi.nlm.nih.gov/pubmed/36411723 http://dx.doi.org/10.12659/AOT.937988

Ejemplares similares

Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials
por: Lee, Sung-Gyu, et al.
Publicado: (2020)

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
por: Bremer, Sebastian C. B., et al.
Publicado: (2018)

Tacrolimus-induced gingival hyperplasia and recovery from tacrolimus to everolimus switching
por: Oral, Alihan, et al.
Publicado: (2019)

Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics
por: Itohara, Kotaro, et al.
Publicado: (2022)

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
por: De Simone, P, et al.
Publicado: (2012)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

Everolimus/prednisolone/tacrolimus: COVID-19 infection: case report
Publicado: (2021)

Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review
por: Diaz, Natalia A., et al.
Publicado: (2021)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis
por: Wei, Kai-Che, et al.
Publicado: (2015)

Tacrolimus-Induced Salt Losing Nephropathy Resolved After Conversion to Everolimus
por: Sayin, Burak
Publicado: (2015)

Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
por: Wagle Shukla, Aparna, et al.
Publicado: (2023)

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017)

Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus
por: Nishioka, Shun, et al.
Publicado: (2021)

Generic Tacrolimus (Tacrobell(®)) Shows Comparable Outcomes to Brand-Name Tacrolimus in the Long-Term Period After Adult Deceased Donor Liver Transplantation
por: Kim, Jong Man, et al.
Publicado: (2019)

Everolimus/prednisone/tacrolimus: Primary lung adenocarcinoma and lymphangitic carcinomatosis: case report
Publicado: (2018)

Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
por: Sahman, Majda, et al.
Publicado: (2021)

Early use of everolimus improved renal function after adult deceased donor liver transplantation
por: Lee, Seohee, et al.
Publicado: (2021)

Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients
por: Philips, Cyriac Abby, et al.
Publicado: (2021)

Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years
por: Saliba, Faouzi, et al.
Publicado: (2019)

Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers after Renal Transplantation
por: Thölking, Gerold, et al.
Publicado: (2020)

Laparoscopic donor hepatectomy: First experience from Indian sub-continent
por: Vijai, Natesan Anand, et al.
Publicado: (2019)

Effects of ABCB1 DNA methylation in donors on tacrolimus blood concentrations in recipients following liver transplantation
por: Shi, Chengcheng, et al.
Publicado: (2022)

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation
por: Chapman, William C., et al.
Publicado: (2017)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus
por: Shihab, F., et al.
Publicado: (2017)

Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial
por: Nashan, Björn, et al.
Publicado: (2021)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Endometriosis and oocyte quality: an analysis of 13 614 donor oocyte recipient and autologous IVF cycles
por: Kamath, Mohan S, et al.
Publicado: (2022)

Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases
por: Hernandez-Alejandro, Roberto, et al.
Publicado: (2022)

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
por: Wu, Zhengshan, et al.
Publicado: (2013)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Simultaneous Determination of Cyclosporine A, Tacrolimus, Sirolimus, and Everolimus in Whole-Blood Samples by LC-MS/MS
por: Karapirli, Mustafa, et al.
Publicado: (2012)

The Synergistic Effect of Tacrolimus (FK506) or Everolimus and Azoles Against Scedosporium and Lomentospora Species In Vivo and In Vitro
por: Wang, Zikuo, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
por: Nashan, Bjorn, et al.
Publicado: (2015)

Cascade plasmapheresis (CP) as a preconditioning regime in ABO-incompatible live related donor liver transplants (ABOi-LDLT)
por: Tiwari, Aseem Kumar, et al.
Publicado: (2014)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4q0ojpac0fl7oc51dk0kc3ih6